Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.
You may also be interested in...
Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
Artificial intelligence won’t transform pharma R&D, at least not anytime soon. But it is already impacting health care delivery and clinical trials.